Bringing next generation single-use sensor technologies to the life science market

14 Mar 2019

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Pall Corporation has partnered with Broadley-James Corporation to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors. With applications across upstream and downstream unit operations, the sensor will be integrated into Pall Biotech’s single-use (SU) technologies, as well as other commercially available bioprocessing platforms.

Bringing next generation single-use sensor technologies to the life science market

“Pall’s single-use bioprocessing know-how and Broadley-James’ expertise in sensor development have proven complementary in addressing critical customer pain points in modern bioprocessing,” explained Martin Smith, Chief Technology Officer of Pall Corporation. “In particular, the new single-use pH sensor solution allows us to offer customers the robustness of traditional sensor technologies integrated into their single-use systems.”

The novel SU pH sensors leverage widely accepted glass electrochemical technology, the only method that meets international standards for pH measurement. The design includes a calibrated buffer storage environment for the sensor to eliminate previous constraints during pre-integration of glass pH sensors into consumables. Users will be able to operate in closed systems, without sacrificing performance.

“Customers currently rely on calibration data gathered before the sensor is sterilized, which can affect the measurement accuracy,” said Robert Garrahy, Vice-President at Broadley-James. “Our patent-pending new storage solutions design features a known pH buffer, enabling robust pre-use calibration. By pairing trusted technology with cutting-edge design, we are able to offer the best balance of risk reduction and performance.”

The Broadley-James single-use probe and flow cell pH sensors are currently in beta testing and when launched will be available exclusively through Pall Biotech. Parallel technical and process development support is also available to optimize use of this new technology.

Read More

Related news

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

Thermo Fisher Scientific signs agreement with Lilly Oncology for companion diagnostic

10 Sep 2019

Strategic agreement utilizes FDA-approved next-generation sequencing Oncomine Dx Target Test to identify RET-altered NSCLC and thyroid cancer patients who may be suitable for Lilly's RET inhibitor.

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Catalent to open new clinical supply facility in San Diego

Catalent to open new clinical supply facility in San Diego

6 Sep 2019

Will enhance speed to clinic through expanded early-phase clinical supply and oral dose development services.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more 
Velesco Pharma to triple its clinical manufacturing capacity

Velesco Pharma to triple its clinical manufacturing capacity

4 Sep 2019

Company's new building in Wixom, MI replace and consolidate its existing manufacturing site in Kalamazoo, MI.

Read more 
Taiwan's biggest CDMO secures FDA approval

Taiwan's biggest CDMO secures FDA approval

3 Sep 2019

Customers claim Bora's oral solid dosage Zhunan facility is in the top 5 external manufacturing facilities they’ve ever visited in the world.

Read more 
China relaxes import regulations to improve access and availability of affordable medicines

China relaxes import regulations to improve access and availability of affordable medicines

3 Sep 2019

The potential for generics to support the healthcare needs of China is significant.

Read more 
Dutch company receives €20 million for skin cancer diagnostic test

Dutch company receives €20 million for skin cancer diagnostic test

3 Sep 2019

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

Read more